Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients - Amaral, N. B.; Rodrigues, T. S.; Giannini, M. C.; Lopes, M. I.; Bonjorno, L. P.; Menezes, P. I. S. O.; Dib, S. M.; Gigante, S. L. G.; Benatti, M. N.; Rezek, U. C.; Emrich-Filho, L. L.; Sousa, B. A.; et al. (Inflammation research, 2023)
Keywords: Allergology; Biomedical and Life Sciences; Biomedicine; Brief Report; Caspase-1; Clinical trials; Colchicine; Colchicine - therapeutic use; Coronaviruses; COVID-19; Cytokine storm; Dermatology; Humans; IL-1β; Immunology; Inflammasomes; Inflammasomes - metabolism; Interleukin 18; Interleukin-1beta - metabolism; Neurology; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; NLR Proteins; Patients; Pharmacology/Toxicology; Placebos; RBR; RBR8jyhxh; Rheumatology; Serum levels; COVID-19; Inflammasome; Colchicine; Cytokines